AFP and hepatocellular carcinoma: Training cohort (AFP or US positive suspected individuals): 85%/93%, 0.928Validation cohort (AFP and US negative individuals): 24/331 patients tested positive and eventually 4/24 develop HCC. None of the negative patients develop HCC. Sensitivity/specificity: 100%/94%